GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (NAS:HRTX) » Definitions » Cyclically Adjusted Price-to-FCF

Heron Therapeutics (Heron Therapeutics) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2024)


View and export this data going back to 1987. Start your Free Trial

What is Heron Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Heron Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Heron Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics Cyclically Adjusted Price-to-FCF Chart

Heron Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Heron Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Heron Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Heron Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heron Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Heron Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Heron Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Heron Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.063/131.7762*131.7762
=-0.063

Current CPI (Mar. 2024) = 131.7762.

Heron Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.526 100.560 -0.689
201409 -0.666 100.428 -0.874
201412 -0.475 99.070 -0.632
201503 -0.680 99.621 -0.899
201506 -0.516 100.684 -0.675
201509 -0.563 100.392 -0.739
201512 -0.650 99.792 -0.858
201603 -0.916 100.470 -1.201
201606 -0.761 101.688 -0.986
201609 -0.937 101.861 -1.212
201612 -0.998 101.863 -1.291
201703 -1.020 102.862 -1.307
201706 -0.604 103.349 -0.770
201709 -0.748 104.136 -0.947
201712 -0.838 104.011 -1.062
201803 -0.967 105.290 -1.210
201806 -0.863 106.317 -1.070
201809 -0.506 106.507 -0.626
201812 -0.473 105.998 -0.588
201903 -0.652 107.251 -0.801
201906 -0.318 108.070 -0.388
201909 -0.306 108.329 -0.372
201912 -0.346 108.420 -0.421
202003 -0.397 108.902 -0.480
202006 -0.639 108.767 -0.774
202009 -0.470 109.815 -0.564
202012 -0.604 109.897 -0.724
202103 -0.468 111.754 -0.552
202106 -0.643 114.631 -0.739
202109 -0.537 115.734 -0.611
202112 -0.447 117.630 -0.501
202203 -0.440 121.301 -0.478
202206 -0.280 125.017 -0.295
202209 -0.332 125.227 -0.349
202212 -0.319 125.222 -0.336
202303 -0.211 127.348 -0.218
202306 -0.229 128.729 -0.234
202309 -0.069 129.860 -0.070
202312 0.015 129.419 0.015
202403 -0.063 131.776 -0.063

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Heron Therapeutics  (NAS:HRTX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Heron Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Heron Therapeutics (Heron Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.
Executives
William P Forbes officer: EVP, Chief Development Officer C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Adam Morgan other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Ira Duarte officer: EVP, Chief Financial Officer 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Velan Capital Master Fund Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
David Efraim Rosen other: See Footnote 1 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Rubric Capital Management Lp other: See Footnote 1 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Balaji Venkataraman other: See Footnote 2 FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Kimberly Manhard director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Waage Christian director RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121